Please select the option that best describes you:

In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?  



Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at MedStar Georgetown Cancer Institute
How long would you continue the olaparib? Is it 1 ...
Medical Oncologist at IHA Hem Onc Consult
1 year
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more